Orsenix Eyes Opportunity For Oral Arsenic Leukemia Therapy
Executive Summary
Teva's Trisenox, an IV formulation of arsenic trioxide, was recently approved by the FDA as a first-line treatment for acute promyelocytic leukemia but Incyte founder Kris Vaddi's Orsenix believes its Phase III-ready oral version will take over the market.